These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://jakubjoiu797707.blogsvila.com/39433892/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide